Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23215304 | 1.00 | MGLL (0.36) | MGLLDDR1SFRP1TLR9TLR8 | |
| SCHEMBL23216160 | 1.00 | MGLL (0.36) | MGLLDDR1SFRP1TLR9TLR8 | |
| Trifluoroacetic Acid SCHEMBL23215307 | 0.83 | CCR4 (0.38) | MGLLDDR1SFRP1TLR9TLR8 | |
| SCHEMBL23230919 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL29745489 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL29745455 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL23230965 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL23230918 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL29745599 | 0.81 | TLR9 (0.37) | DDR1SFRP1TLR9TLR8TLR7 | |
| SCHEMBL23215529 | 0.81 | DDR1 (0.37) | MGLLDDR1SFRP1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | MGLL 3399/4885DDR1 2844/4885SFRP1 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.